引用本文:黄 倩,张 坤,张 霞,叶俊生,赖彦华,吴志贤.CENPM表达在肝移植术后肝癌复发患者中的临床意义[J].中国临床新医学,2020,13(12):1199-1203.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 70次   下载 71 本文二维码信息
码上扫一扫!
分享到: 微信 更多
CENPM表达在肝移植术后肝癌复发患者中的临床意义
黄 倩,张 坤,张 霞,叶俊生,赖彦华,吴志贤
350122 福州,福建中医药大学附属第三人民医院肝胆科(黄 倩);361100 厦门,厦门大学附属翔安医院肝胆外科(张 坤);350025 福州,联勤保障部队第900医院肝胆内科(张 霞,吴志贤);510515 广州,南方医科大学南方医院肾移植科(叶俊生);530021 南宁,广西壮族自治区人民医院移植科(赖彦华)
摘要:
[摘要] 目的 研究促肝癌基因着丝粒蛋白M(CENPM)在肝移植术后肝癌复发患者中表达与临床特征的相关性以及对预后的影响。方法 纳入肝移植术后肝癌复发患者82例,未复发组40例,对切除肝标本进行免疫组织化学染色观察CENPM表达水平,收集患者临床资料及预后情况,分析高表达组与低表达组临床特征、复发特征和预后的差异。结果 复发患者82例中位随访时间为22(8~38)个月,CENPM高表达比例为70.7%,而未复发组为50.0%,差异有统计学意义(P=0.025)。复发患者中,高表达组与低表达组相比,无疾病生存时间差异有统计学意义(P=0.036);高表达组总体生存时间低于低表达组,差异有统计学意义(P=0.019)。结论 CENPM表达与肝移植术后肝癌较快复发及转移有关,并影响患者预后。
关键词:  着丝粒蛋白M  肝癌  肝移植  移植后复发
DOI:10.3969/j.issn.1674-3806.2020.12.04
分类号:R 657.3
基金项目:福建省自然科学基金面上项目(编号:2020J011131);福建省科技创新联合资金项目(编号:2019Y9044)
Clinical significance of CENPM expression in patients with recurrent liver cancer after liver transplantation
HUANG Qian, ZHANG Kun, ZHANG Xia, et al.
Department of Hepatobiliary Disease, the Third People′s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China
Abstract:
[Abstract] Objective To study the correlation between the expression of the liver cancer-promoting gene centromere protein M(CENPM) in patients with recurrent liver cancer after liver transplantation and the clinical characteristics and its influence on the prognosis. Methods Eighty-two patients with recurrent liver cancer after liver transplantation and 40 patients without recurrence(the nonrecurrent group) were enrolled in the study. The expression of CENPM was detected by immunohistochemical staining in the resected liver specimens. The clinical data and prognosis of the patients were collected. The differences in clinical features, recurrence characteristics and prognosis between the high expression group and the low expression group were analyzed. Results The median follow-up time of the 82 patients with recurrent liver cancer was 22(8~38)months. The high expression ratio of CENPM was 70.7% in the 82 patients with recurrent liver cancer, and 50.0% in the nonrecurrent group, and the difference was statistically significant(P=0.025). In the patients with recurrence, the difference in disease-free survival time between the high expression group and the low expression group was statistically significant(P=0.036), and the overall survival time of the high expression group was significantly lower than that of the low expression group(P=0.019). Conclusion The expression of CENPM is related to the faster recurrence and metastasis of liver cancer after liver transplantation and affects the prognosis of the patients.
Key words:  Centromere protein M(CENPM)  Liver cancer  Liver transplantation  Recurrence after transplantation